Dow Jones
38.225,66 +322,37 (+0,85%) Nasdaq
15.840,96 +235,48 (+1,51%) Nikkei 225
38.236,07 -37,98 (-0,10%) EUR/USD
1,0731 +0,0013 (+0,12%) Bitcoin EUR
55.310,61 +2.160,42 (+4,06%) CMC Crypto 200
1.277,20 +6,46 (+0,51%)
Pulmonx Corporation (LUNG)
Dopo ore:
| Chiusura precedente | 7,72 |
| Aperto | 9,74 |
| Denaro | 9,35 x 200 |
| Lettera | 9,40 x 200 |
| Min-Max giorno | 8,85 - 9,98 |
| Intervallo di 52 settimane | 7,11 - 14,84 |
| Volume | |
| Media Volume | 592.604 |
| Capitalizzazione | 364,055M |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,60 |
| Prossima data utili | 31 lug 2024 - 05 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 16,20 |
GlobeNewswirePulmonx Announces CFO Transition and Record Preliminary Third Quarter 2023 Revenue
Derrick Sung steps down from his position as Chief Financial Officer to pursue another opportunity; John McKune appointed Interim Chief Financial OfficerPreliminary, unaudited third quarter 2023 revenue expected to be approximately $17.6 millionManagement to host conference call on October 30, 2023 to discuss third quarter 2023 financial results REDWOOD CITY, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally in
- GlobeNewswire
Pulmonx to Participate at Upcoming Investor Conferences
REDWOOD CITY, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences. Pulmonx management is scheduled to participate in a fireside chat at the 2023 Wells Fargo Healthcare Conference in Boston on Wednesday, September 6, 2023, at 11:15am PT / 2:15pm ET. Interested parties may access a live and archived web
- GlobeNewswire
Pulmonx Reports Second Quarter 2023 Financial Results
REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2023 ended June 30, 2023. Recent Highlights Achieved record worldwide revenue of $17.2 million in the second quarter of 2023, a 23% increase over the same period last yearDelivered a new high of $11.0 million in U.S. revenue in the second quarter of 202
